EGFR and gallbladder cancer: To evaluate the prevalence and genomic profile of EGFR‐amplified BTC, we reviewed the previously reported tissue‐genome sequence datasets of 707 BTC samples (51 samples of cholangiocarcinoma [Firehose Legacy, TCGA], 412 samples of intrahepatic cholangiocarcinoma, and 244 samples of gallbladder cancer), available at c‐BioPortal (https://www.cbioportal.org/) [9, 10, 11, 12].